S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Compugen Stock Forecast, Price & News

-0.07 (-1.52%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
656,674 shs
Average Volume
1.13 million shs
Market Capitalization
$310.63 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

Compugen logo

About Compugen

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2 million
Book Value
$1.44 per share


Net Income
$-29.70 million
Pretax Margin




Free Float
Market Cap
$310.63 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

1.77 out of 5 stars

Medical Sector

848th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

129th out of 201 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Compugen (NASDAQ:CGEN) Frequently Asked Questions

Is Compugen a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Compugen stock.
View analyst ratings for Compugen
or view top-rated stocks.

How has Compugen's stock price been impacted by Coronavirus (COVID-19)?

Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CGEN shares have decreased by 61.6% and is now trading at $4.54.
View which stocks have been most impacted by COVID-19

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Compugen

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) announced its quarterly earnings results on Friday, November, 12th. The biotechnology company reported ($0.07) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.06. During the same quarter last year, the company posted ($0.09) EPS.
View Compugen's earnings history

What price target have analysts set for CGEN?

3 Wall Street analysts have issued 1-year target prices for Compugen's stock. Their forecasts range from $16.00 to $19.00. On average, they anticipate Compugen's share price to reach $17.67 in the next year. This suggests a possible upside of 289.1% from the stock's current price.
View analysts' price targets for Compugen
or view top-rated stocks among Wall Street analysts.

Who are Compugen's key executives?

Compugen's management team includes the following people:
  • Anat Cohen-Dayag, President, Chief Executive Officer & Director
  • Ari Krashin, Chief Operating & Financial Officer
  • Henry Adewoye, Chief Medical Officer
  • Zurit Levine, Vice President-Technology Innovation
  • Tsipi Keren-Lehrer, Vice President-Business Development

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen CEO Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among Compugen's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (10.27%), BlackRock Inc. (3.71%), Morgan Stanley (2.37%), Rock Springs Capital Management LP (1.88%), Artisan Partners Limited Partnership (1.17%) and Renaissance Technologies LLC (0.98%).

Which institutional investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Nikko Asset Management Americas Inc., Jane Street Group LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC, Marshall Wace LLP, Squarepoint Ops LLC, and Creative Planning.

Which institutional investors are buying Compugen stock?

CGEN stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., UBS Group AG, Geode Capital Management LLC, Trexquant Investment LP, Two Sigma Advisers LP, Raymond James & Associates, and Rock Springs Capital Management LP.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $4.54.

How much money does Compugen make?

Compugen has a market capitalization of $310.63 million and generates $2 million in revenue each year. The biotechnology company earns $-29.70 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Compugen have?

Compugen employs 45 workers across the globe.

When was Compugen founded?

Compugen was founded in 1993.

What is Compugen's official website?

The official website for Compugen is www.cgen.com.

Where are Compugen's headquarters?

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at (723) 765-8585, via email at [email protected], or via fax at 972-3765-8555.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.